Actively Recruiting
Speckle Tracking Echocardiography as a Tool for Early Diagnosis of Impaired Fetal Growth Twin Pregnancies
Led by University Hospital, Ghent · Updated on 2023-09-26
360
Participants Needed
3
Research Sites
240 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Ghent
Lead Sponsor
K
KU Leuven
Collaborating Sponsor
AI-Summary
What this Trial Is About
In this project there are 2 time points during the pregnancy included, namely at 21 weeks and 30 weeks of gestation, to measure the predictive values of FGR, strain and strain rate. The fetal growth parameters will be collected at the same time points, to define the growth (differences) throughout gestation of both fetuses. A maternal blood sample will be taken at 21 weeks of gestation to identify the level of exposure to air pollution (black carbon) and the level of biochemical markers of placental dysfunction. Doppler ultrasounds will be used for antenatal identification of placenta insufficiency. At birth, umbilical cord blood and the placenta will be collected. The placenta will be examined, to identify morphological findings which are associated with FGR. The umbilical cord blood and placental biopsy will be used for the level of exposure to air pollution and the level of oxidative stress. One to three days after birth, neonatal strain and strain rate will be measured to define postnatal cardiac remodeling as well as the neonatal blood pressure as cardiovascular risk factor.
CONDITIONS
Official Title
Speckle Tracking Echocardiography as a Tool for Early Diagnosis of Impaired Fetal Growth Twin Pregnancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Singleton or dichorionic twin pregnancy
- Pregnant women 21 weeks (± 2 weeks) of gestation at the first visit
- Women aged 18 years or older
You will not qualify if you...
- Women pregnant with monochorionic twins or multiples of higher order (3 or more siblings)
- Fetal arrhythmia
- Known fetal congenital or genetic abnormalities
- Any suspicion of congenital fetal anomalies affecting cardiac function
- Pre-existing maternal hypertensive disease
- Autoimmune diseases including systemic lupus erythematosus
- History of stillbirth
- Diabetes mellitus (mother)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Ghent University Hospital
Ghent, Belgium, 9000
Actively Recruiting
2
Universitair ziekenhuis Leuven
Leuven, Belgium, 3000
Not Yet Recruiting
3
Maxima medical center
Eindhoven, Netherlands, 5631
Not Yet Recruiting
Research Team
E
Eline Meireson
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here